A proposal for value informed, affordable (“via”) prices for innovative medicines

References

• Council of the European Union. Council Conclusions on Innovation for the Benefit of Patients. Official Journal of the European Union. December 2014.
   Google Scholar
• Annemans L, Cleemput I, Hulstaert F, et al. Valorising and creating access to innovative medicines in the European Union. Front Pharmacol. 2011;2:Article 57.
   PubMed Web of Science ®Google Scholar
• Ministerial Statement ‘The next generation of health reforms’. OECD Health Ministerial Meeting. 17 January 2017. Available from: http://www.oecd.org/health/ministerial/ministerial-statement-2017.pdf [Accessed 15 April 2019].
   Google Scholar
• Luzzatto L, Hyry HI, Schieppati A, et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet. 2018;392:791–794.
   PubMed Web of Science ®Google Scholar
• Howard DH, Bach PB, Berndt ER, et al. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29:139–162.
   PubMed Web of Science ®Google Scholar
• Prasad V, De Jesús K, Mailankody S, et al. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14:381–389.
   PubMed Web of Science ®Google Scholar
• Cohen D. Cancer drugs: high price, uncertain value. BMJ. 2017;359:j4543.
   PubMed Web of Science ®Google Scholar
• Expert Panel on Effective Ways of Investing in Health (EXPH). Opinion on innovative payment models for high-cost innovative medicines. Brussels: European Commission; January 2018.
   Google Scholar
• Neumann PJ, Bliss SK, Chambers JD. Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries. Health Aff. 2012;31:700–708.
   PubMed Web of Science ®Google Scholar
• Santos AS, Guerra-Junior AA, Godman B, et al. Cost-effectiveness thresholds: methods for setting and examples from around the world. Expert Rev Pharmacoecon Outcomes Res. 2018;18:277–288.
   PubMed Web of Science ®Google Scholar
• Svensson M, Nilsson FOL, Arnberg K, et al. Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness. Pharmacoeconomics. 2015;33:1229–1236.
   PubMed Web of Science ®Google Scholar
• Pricing of cancer medicines and its impacts. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• Dholakia UM. When cost-plus pricing is a good idea. Harvard Business Review. July 12, 2018. 4 p.
   Google Scholar
• Ghinea N, Lipworth W, Kerridge I. Propaganda or the cost of innovation? Challenging the high price of new drugs. BMJ. 2016;352:i1284.
   PubMedGoogle Scholar
• Uyl-De Groot C, Löwenberg B. Sustainability and affordability of cancer drugs: a novel pricing model. Nat Rev Clin Oncol. 2018;15:405–406.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Willke RJ, Garrison LP, et al. A health economics approach to US value assessment frameworks—introduction: an ISPOR special task force report [1]. Value in Health. 2018;21:119–123.
   PubMed Web of Science ®Google Scholar
• Nord E. Concerns for the worse off: fair innings versus severity. Soc Sci Med. 2005;60:257–263.
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Saito S, Shimozuma K, et al. Societal preferences for interventions with the same efficiency: assessment and application to decision making. Appl Health Econ Health Policy. 2016;14:375–385. Jun
   PubMed Web of Science ®Google Scholar
• Richardson J, Iezzi A, Maxwell A. How important is severity for the evaluation of health services: new evidence using the relative social willingness to pay instrument. Eur J Health Econ. 2017;18:671–683.
   PubMed Web of Science ®Google Scholar
• Annemans L, Aymé S, Le Cam Y, et al. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL). Orphanet J Rare Dis. 2017;12:50.
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Doshi JA, Garrison LP, et al. Defining elements of value in health care—a health economics approach: an ISPOR Special Task Force report [3]. Value Health. 2018;21:131–139.
   PubMed Web of Science ®Google Scholar
• Taylor D, Craig T. Value based pricing for NHS medicines: magic bullet, counterfeit treatment or the mixture as before? Health Econ Policy Law. 2009;4:515–526.
   PubMed Web of Science ®Google Scholar
• Danzon PM, Drummond MF, Towse A, et al. Objectives, budgets, thresholds, and opportunity costs—a health economics approach: an ISPOR Special Task Force Report [4]. Value in Health. 2018;21:140–145.
   PubMed Web of Science ®Google Scholar
• Stolk EA, Brouwer WB, Busschbach JJ. Rationalising rationing: economic and other considerations in the debate about funding of Viagra. Health Pol. 2002;59:53–63. Jan
   PubMed Web of Science ®Google Scholar
• Schlander M, Garattini S, Holm S, et al. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res. 2014;3:399–422.
   PubMed Web of Science ®Google Scholar
• Stolk EA, Van Donselaar G, Brouwer WB, et al. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall. Pharmacoeconomics. 2004;22:1097–1107.
   PubMedGoogle Scholar
• ZIN. Kosteneffectiviteit in de praktijk (cost-effectiveness in practice) – in Dutch, 26 June 2015.
   Google Scholar
• Lindemark F, Norheim OF, Johansson KA. Making use of equity sensitive QALYs: a case study on identifying the worse off across diseases. Cost Eff Resour Alloc. 2014;12:16.
   PubMed Web of Science ®Google Scholar
• Reckers-Droog VT, van Exel NJA, Brouwer WBF, et al. Looking back and moving forward: on the application of proportional shortfall in healthcare priority setting in the Netherlands. Health Pol. 2018;122:621–629.
   PubMed Web of Science ®Google Scholar
• Cleemput I, Devriese S, Kohn L, et al. Incorporating societal preferences in reimbursement decisions – Relative importance of decision criteria according to Belgian citizens. Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE); 2014. KCE Reports 234. D/2014/10.273/91.
   Google Scholar
• Godman B, Bucsics A, Vella Bonanno P, et al. Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Public Health. 2018;6:328.
   PubMed Web of Science ®Google Scholar
• Wahlster P, Goetghebeur M, Kriza C, et al. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA). BMC Health Serv Res. 2015;15:262.
   PubMed Web of Science ®Google Scholar
• Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics. 2006;24:1121–1131.
   PubMed Web of Science ®Google Scholar
• Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA. 2014;312:593–594.
   PubMed Web of Science ®Google Scholar
• Niezen MG, de Bont A, Busschbach JJ, et al. Finding legitimacy for the role of budget impact in drug reimbursement decisions. Int J Technol Assess Health Care. 2009;25:49–55.
   PubMed Web of Science ®Google Scholar
• Towse A, Mauskopf JA. Affordability of new technologies: the next frontier. Value Health. 2018;21:249–251.
   PubMed Web of Science ®Google Scholar
• Griffits EA, et al. Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold. Clinicoecon Outcomes Res. 2015;7:463–476.
   PubMed Web of Science ®Google Scholar
• Paulden M, Stafinski T, Menon D, et al. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. Pharmacoeconomics. 2015; 33:255–269.
   PubMed Web of Science ®Google Scholar
• Phelps CE, Lakdawalla DN, Basu A, et al. Approaches to aggregation and decision making—a health economics approach: an ISPOR Special Task Force Report [5]. Value Health. 2018;21:146–154.
   PubMed Web of Science ®Google Scholar
• Charakopou M, Majer IM, Raad J de, et al. Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006–2013. Value Health. 2015;18:284–291.
   PubMed Web of Science ®Google Scholar